Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies

Journal of Allergy and Clinical Immunology

Volumn 128, Issue 1, 2011, Pages 153-159.e4

  Sheffer, Albert L ^a   Campion, Marilyn ^b   Levy, Robyn J ^c   Li, H Henry ^d   Horn, Patrick T ^e   Pullman, William E ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Family Allergy and Asthma Center ^*

^c Family Allergy and Asthma Center   (United States)

^d Institute for Asthma and Allergy   (United States)

^e Dyax Corp   (United States)

Author keywords

Ecallantide; Evaluation of DX 88's Effects in Mitigating Angioedema 3 and 4; hereditary angioedema; mean symptom complex severity; plasma kallikrein inhibitor; treatment outcome score

Indexed keywords

ECALLANTIDE; KALLIKREIN; PLACEBO;

ACUTE DISEASE; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL ANATOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SELF REPORT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79959818300     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.03.006     Document Type: Article

References (22)

1. M.M. Gompels, R.J. Lock, M. Abinun, C.A. Bethune, G. Davies, and C. Grattan C1 inhibitor deficiency: consensus document Clin Exp Immunol 139 2005 379 394 (Pubitemid 40333248)
2. B.L. Zuraw Clinical practice. Hereditary angioedema N Engl J Med 359 2008 1027 1036
3. L. Schneider, W. Lumry, A. Vegh, A.H. Williams, and T. Schmalbach Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor J Allergy Clin Immunol 120 2007 416 422 (Pubitemid 47102386)
4. T. Hara, A. Shiotani, H. Matsunaka, T. Yamanishi, H. Oka, and T. Ishiguchi Hereditary angioedema with gastrointestinal involvement: endoscopic appearance Endoscopy 31 1999 322 324 (Pubitemid 29229373)
5. A.L. Sheffer, J.M. Craig, K. Willms-Kretschmer, K.F. Austen, and F.S. Rosen Histopathological and ultrastructural observations on tissues from patients with hereditary angioneurotic edema J Allergy 47 1971 292 297
6. Cinryze (C1 esterase inhibitor [human]) package insert. New York: Lev Pharmaceuticals, Inc. Available at: http://www.cinryze.com/PDF/Cinryze-PI.pdf. Accessed October 6, 2009.
7. Kalbitor (DX-88 [ecallantide]) package insert 2009 Dyax Corporation Cambridge (MA)
8. Berinert. (C1 esterase inhibitor [human]) package insert 2009 CSL Behring GmbH Marburg (Germany)
9. A. Banerji, D.E. Sloane, and A.L. Sheffer Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema Ann Allergy Asthma Immunol 100 suppl 2 2008 S19 S22
10. H. Farkas, L. Jakab, G. Temesszentandrasi, B. Visy, G. Harmat, and G. Füst Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy J Allergy Clin Immunol 120 2007 941 947 (Pubitemid 47531846)
11. D.E. Sloane, C.W. Lee, and A.L. Sheffer Hereditary angioedema: safety of long-term stanozolol therapy J Allergy Clin Immunol 120 2007 654 658 (Pubitemid 47320768)
12. M.M. Frank, and H. Jiang New therapies for hereditary angioedema: disease outlook changes dramatically J Allergy Clin Immunol 121 2008 272 280
13. A. Lehmann Ecallantide(DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery Expert Opin Biol Ther 8 2008 1187 1199
14. M. Cicardi, R.J. Levy, D.L. McNeil, H.H. Li, A.L. Sheffer, and M. Campion Ecallantide for the treatment of acute attacks in hereditary angioedema N Engl J Med 363 2010 523 531
15. R.J. Levy, W.R. Lumry, D.L. McNeil, H.H. Li, M. Campion, and P.T. Horn EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema Ann Allergy Asthma Immunol 104 2010 523 529
16. M. Vernon, A. Rentz, W. Wyrwich, M.V. White, and A. Grienenberger Psychometric validation of 2 patient-reported outcome (PRO) measures to assess symptom severity and changes in symptoms in hereditary angioedema (HAE) Qual Life Res 18 2009 929 939
17. H.A. Sampson, A. Munoz-Furlong, R. Campbell, N.F. Adkinson, S.A. Bock, and A. Branum Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium J Allergy Clin Immunol 117 2006 391 397 (Pubitemid 43190153)
18. A.E. Davis III The pathophysiology of hereditary angioedema Clin Immunol 114 2005 3 9
19. B.L. Zuraw, and S.C. Christiansen Pathogenesis and laboratory diagnosis of hereditary angioedema Allergy Asthma Proc 30 2009 487 492
20. K. Bork, G. Meng, P. Staubach, and J. Hardt Hereditary angioedema: new findings concerning symptoms, affected organs, and course Am J Med 119 2006 267 274 (Pubitemid 43255068)
21. M. Cicardi, R.J. Levy, D.L. McNeil, H.H. Li, A.L. Sheffer, and M. Campion Ecallantide for the treatment of acute attacks in hereditary angioedema N Engl J Med 363 2010 523 531
22. R.J. Levy, W.R. Lumry, D.L. McNeil, H.H. Li, M. Campion, and P.T. Horn EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema Ann Allergy Asthma Immunol 104 2010 523 529